NEW YORK (GenomeWeb) – Vermillion said yesterday that its Aspira Labs subsidiary has won out-of-state provider status with Medi-Cal, California's Medicaid program, for its OVA1 ovarian cancer test.
The status gives the company access to more than 12 million Medi-Cal beneficiaries, representing roughly one-third of the covered lives in California, Vermillion said.
"This new status is an expansion to our prior Medi-Cal coverage and is key to reaching the entire Medicaid base, as well as expanding OVA1 access in the state with the largest US population," Valerie Palmieri, president and CEO of Vermillion, said in a statement. "It should also create additional opportunities with healthcare systems and other medical insurers in the California market."
OVA1 is a proteomic test intended for use in patients with an adnexal mass to determine prior to surgery whether the mass is likely malignant or benign and help physicians decide if a patient should be passed on to a gynecologic oncologist for the procedure.